Related Experiment Videos
Sclerosing cholangitis in ulcerative colitis. A follow-up study
Scandinavian Journal of Gastroenterology
|January 1, 1982
Summary
Hepatobiliary disease, including sclerosing cholangitis, affects ulcerative colitis patients. Many remain asymptomatic for years, with limited value in standard tests for tracking disease progression.
Area of Science:
- Gastroenterology
- Hepatology
- Internal Medicine
Background:
- Ulcerative colitis (UC) is associated with various hepatobiliary diseases.
- Hepatobiliary complications can significantly impact UC patient health and prognosis.
Purpose of the Study:
- To investigate the prevalence and progression of hepatobiliary disease in patients with ulcerative colitis.
- To evaluate the utility of clinical, laboratory, and imaging findings in monitoring sclerosing cholangitis progression in UC patients.
Main Methods:
- Retrospective analysis of 336 ulcerative colitis patients from 1974-1978.
- Endoscopic retrograde cholangiography (ERC) and liver biopsies were used for diagnosis and monitoring.
- Long-term follow-up of patients diagnosed with hepatobiliary disease, specifically sclerosing cholangitis.
Main Results:
- 14% of UC patients developed hepatobiliary disease; 19 patients were diagnosed with sclerosing cholangitis (SC) after ERC.
- Of 16 followed SC patients, 10 remained asymptomatic, 4 had non-progressive symptoms, and 2 developed advanced liver disease.
- Despite evidence of cholangiographic progression in most patients, symptoms, lab values, and biopsy findings showed limited worsening.
Conclusions:
- Sclerosing cholangitis in ulcerative colitis patients can be asymptomatic for extended periods.
- Standard clinical, laboratory, and liver biopsy assessments have limited value in evaluating the progression of SC.
- Endoscopic retrograde cholangiography reveals disease progression more sensitively than other parameters.